Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.43 |
| ▸ | GRM5 | P41594 | 10/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 5/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.39 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16039939 | 0.84 | HTR6 (0.51) | HTR6GRM1GRM5PDK4CDK9 | |
| SCHEMBL16039506 | 0.84 | CCNT1 (0.55) | HTR6CDK9CCNT1 | |
| SCHEMBL16040507 | 0.84 | CDK9 (0.46) | HTR6GRM1GRM5PDK4CDK9 | |
| SCHEMBL4318186 | 0.84 | HTR6 (0.53) | HTR6GRM1GRM5PDK4CDK9 | |
| SCHEMBL16040458 | 0.80 | HTR6 (0.51) | HTR6GRM1GRM5PDK4CDK9 | |
| SCHEMBL17535060 | 0.80 | CDK9 (0.51) | CDK9CCNT1 | |
| SCHEMBL16050699 | 0.80 | CDK9 (0.44) | HTR6GRM1GRM5PDK4CDK9 | |
| SCHEMBL5001708 | 0.79 | HTR6 (0.53) | HTR6GRM1GRM5PDK4TNK2 | |
| SCHEMBL16052375 | 0.79 | CDK9 (0.43) | HTR6GRM1GRM5CDK9CCNT1 | |
| SCHEMBL17535031 | 0.79 | CDK9 (0.43) | HTR6GRM1GRM5PDK4CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073922-B2 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | HTR6 3977/4885GRM1 2123/4885GRM5 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.